Suchergebnisse - "Kang, Yoon-Koo"

PubPharm (657)

1

Clinical and Biomarker Analysis of a Phase I/II Study of PDR001 plus Imatinib for Advanced Treatment-refractory Gastrointestinal Stromal Tumors

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Kim, H. | Ryu, M. | Park, Y. | +3

2

Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma : final analysis of the randomized phase 2 FIGHT trial

enthalten in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association | 2024

von Wainberg, Z. | Kang, Y. | Lee, K. | +15

3

Adjuvant treatment for locally advanced gastric cancer : an Asian perspective

enthalten in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association | 2024

von Kim, H. | Ryu, M. | Kang, Y.

4

Letter to the editor : 5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer

enthalten in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association | 2024

von Kim, H. | Ryu, M. | Lee, J. | +1

CommentOn: Gastric Cancer. 2024 Jan;27(1):155-163. - PMID 37989806

5

Prognostic value of mismatch repair deficiency in patients receiving first-line fluoropyrimidine plus platinum for metastatic, recurrent, or unresectable gastric cancer

enthalten in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association | 2024

von Oh, C. | Kim, E. | Chae, H. | +4

6

Adjuvant treatment for locally advanced gastric cancer: an Asian perspective

enthalten in: Gastric cancer | 2024

von Kim, H. | Ryu, M. | Kang, Y.

7

Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study) : an international, randomized, placebo-controlled, phase 3 trial

enthalten in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association | 2024

von Kang, Y. | Ryu, M. | Di Bartolomeo, M. | +15

8

Ripretinib versus sunitinib in gastrointestinal stromal tumor : ctDNA biomarker analysis of the phase 3 INTRIGUE trial

enthalten in: Nature medicine | 2024

von Heinrich, M. | Jones, R. | George, S. | +26

9

Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial

enthalten in: Gastric cancer | 2024

von Wainberg, Z. | Kang, Y. | Lee, K. | +15

10

Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial

enthalten in: Gastric Cancer | 2024

von Kang, Y. | Ryu, M. | Di Bartolomeo, M. | +15

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[66]